Get the Stockscreener App
79.45
0.28%
-0.22
After Hours:
79.40
-0.05
-0.06%
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $79.45, with a volume of 193.82K.
It is down -0.28% in the last 24 hours and down -4.82% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$79.67
Open:
$79.73
24h Volume:
193.82K
Relative Volume:
1.00
Market Cap:
$13.23B
Revenue:
$3.47B
Net Income/Loss:
$668.83M
P/E Ratio:
21.39
EPS:
3.7138
Net Cash Flow:
$253.46M
1W Performance:
+0.11%
1M Performance:
-4.82%
6M Performance:
+8.32%
1Y Performance:
+18.81%
1-Day Range:
$79.17
$80.96
1-Week Range:
$78.67
$80.96
52-Week Range:
$63.72
$84.46
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Haryana Elections 2024: Capt. Abhimanyu, Savitri Jindal among wealthiest candidates for October 5 polls | Mint - Mint
Global Nicotine Replacement Therapy Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2030 | DelveInsight - GlobeNewswire Inc.
Apni Party's Altaf Bukhari, BJP's Devender Rana among 3 richest candidates in Jammu and Kashmir assembly poll fray | Mint - Mint
Dr. Reddy's Labs ADR Sees RS Rating Rise To 72 - Investor's Business Daily
Dr. Reddy’s Empowers Employees with Stock Options - TipRanks
Smoking Cessation And Nicotine De-addiction Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire Inc.
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited - Business Wire
ADR, GDR Listings of Indian companies - Goodreturns
India Liver Cancer Therapeutics Research Report 2024-2030 Featuring Natco Pharma, Dr. Reddy's Laboratories, Intas Pharmaceuticals, Mylan Pharmaceuticals, Lupin, Biocon, and Hetero Labs - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? - Investor's Business Daily
Weekly Upgrades and Downgrades - MSN
Dr. Reddy’s Approves Employee Share Allotment - TipRanks
Depository receipts regime fails to take off due to Sebi concerns | Mint - Mint
Dr Reddy's Labs shares drop after US FDA gives VIA tag to Vizag facilities - Business Standard
Form N-CSRS Northern Lights Fund For: May 31 - StreetInsider.com
Lenovo Accelerates ‘Smarter AI for All’ with Databricks Collaboration - Business Wire
Dr Reddy's Laboratories Ltd (RDY) Q1 2025 Earnings Call Transcri - GuruFocus.com
Dr. Reddy’s Earnings: Continued Strength in Execution Lifts Valuation, but Shares Still Pricey - Morningstar
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
Dr Reddy’s Laboratories board announces 1:5 stock split - The Economic Times
Q1 results today: ICICI Bank, Dr Reddy's Lab, MCX, Finolex Industries, Punjab National Bank & more to report earnings | Company Business News - Mint
Nestle India And Dr Reddys Laboratories Form Joint Venture Company - NDTV Profit
800% Dividend Payout: Largecap Pharma Stock In Focus Amid Stock Split Consideration; Should You Buy? - Goodreturns
Wipro vs TCS vs Infosys vs HCL Tech: Which IT stock to buy after Q1 results 2024? | Stock Market News - Mint
Infosys share price in focus as ADR jumps over 8% after Q1 results beat estimates | Stock Market News - Mint
GIFT City: Expert panel calls for a new framework for dispute resolution at the IFSC | Today News - Mint
Dr. Reddy’s Laboratories Ltd. ADR Inc. (RDY) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Infosys Q1 results tomorrow: 4 things from revenue growth to deal wins to be watched out for in the earnings show | Stock Market News - Mint
HDFC Bank share declines after BofA downgrades stock to ‘neutral’, cuts target price | Stock Market News - Mint
Market Trading Guide: Dr. Reddy's, Eicher Motors among 6 top stock recommendations for Wednesday - The Economic Times
India Generic Drugs Market Research 2024: Demand for Accessible and Cost-effective Solutions Bolsters Growth ... - GlobeNewswire Inc.
Dr Reddy's, Sun Pharma recall drugs in US due to production issues: USFDA - Business Standard
Dr Reddys Laboratories Ltd Cash Flow Statement - Indiainfoline
Dr Reddys Labs Futures Share Price: Live Nifty/NSE Futures Price Chart - Indiainfoline
Dr Reddys Laboratories Ltd (Dr Reddys Labs) Share Historical Prices and Data - Indiainfoline
HDFC Bank ADR rises 4% after lower FII shareholding in June quarter lifts MSCI weight sentiment | Stock Market News - Mint
Stocks to buy: Dr Reddy's Lab, Cipla among 9 stocks that can rise 6-15% in next 3-4 weeks; do you own any? | Stock Market News - Mint
TCS Q1 earnings on July 11, HCL Tech on July 12; Bajaj Auto, Infosys, Asian Paints results this month - Business Today
Dr. Reddy's Labs Stock Sees Improved Technical Strength - Investor's Business Daily
10 global companies leading their sectors on climate change and carbon transition - Equities News
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug - Zacks Investment Research
FY24 one of the most challenging years in company’s history: Wipro’s Rishad Premji | Company Business News - Mint
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN
From TCS to Infosys, IT stocks jump 2-3% on Accenture's Q3 results. Is the worst over for tech firms? Experts answer | Stock Market News - Mint
Foreign money chasing ADRs as FPIs cite delays in registration, says Jefferies - Moneycontrol
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Stock: A Year of Stock Market Dynamics - The InvestChronicle
India shares higher at close of trade; Nifty 50 up 0.39% - Investing.com India
Dr. Reddy’s Rewards Employees with Stock Options - TipRanks
Infosys to declare Q1FY25 results after board meeting on THIS date; Here's what to expect | Stock Market News - Mint
Billionaire ministers in PM Modi 3.0 cabinet. Who are the 5 richest? Find details here | Mint - Mint
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):